Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer
Exploratory evaluation of safety, tolerability, pharmacokinetics (PK), maximum tolerated dose (MTD), and efficacy of BI 2536 administered in combination with pemetrexed
Carcinoma, Non-Small-Cell Lung
DRUG: BI 2536|DRUG: Pemetrexed
Maximum tolerated dose (MTD) of BI 2536 in combination with pemetrexed, by occurrence of dose limiting toxicities (DLT), up to 3 weeks|Number of patients with adverse events during combination therapy, according to common terminology criteria for adverse events (CTCAE) 3.0, up to 20 weeks
Objective tumor response after combination therapy, according to Response Evaluation Criteria in Solid Tumours (RECIST), up to 20 weeks|Duration of objective tumor response after combination therapy, up to 1 year|Progression free survival (PFS), up to 2 years|Overall survival, up to 2 years|Number of patients with abnormal laboratory findings, up to 20 weeks|Change in Eastern Cooperative Oncology Group (ECOG) performance score, baseline, up to 1 year
Exploratory evaluation of safety, tolerability, pharmacokinetics (PK), maximum tolerated dose (MTD), and efficacy of BI 2536 administered in combination with pemetrexed